Mangalam Drugs and Organics' Q3 FY 2025-26 Quarterly Results
- 16 Jan 2026
Result Summary
- Mangalam Drugs and Organics Ltd reported a 18.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 34.0%.
- Its expenses for the quarter were up by 20.0% QoQ and down 21.8% YoY.
- The net profit increased 33.9% QoQ and decreased 862.8% YoY.
- The earnings per share (EPS) of Mangalam Drugs and Organics Ltd declined at 6.21 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 58.60 | 49.57 | 88.85 | 18.2% | -34.0% |
Total Expenses | 68.43 | 57.01 | 87.48 | 20.0% | -21.8% |
Profit Before Tax | -9.84 | -12.47 | 1.37 | -21.1% | -818.2% |
Tax | 0.00 | -5.12 | 0.08 | -100.0% | -100.0% |
Profit After Tax | -9.84 | -7.35 | 1.29 | 33.9% | -862.8% |
Earnings Per Share | -6.21 | -4.64 | 0.81 | 33.8% | -866.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Mangalam Drugs and Organics Ltd is a company known for its involvement in the pharmaceutical industry, particularly focusing on the manufacturing of bulk drugs and formulations. It plays a significant role in the production of active pharmaceutical ingredients (APIs), which are essential components in the formulation of various medications. The company has a reputation for supplying high-quality pharmaceutical products both domestically and internationally. However, specific recent developments or strategic initiatives undertaken by the company are not provided in the data.
Revenue
In the third quarter of the fiscal year 2026 (Q3FY26), Mangalam Drugs and Organics Ltd reported a total income of ₹58.60 crores. This represents an 18.2% increase compared to the previous quarter (Q2FY26), where the total income was ₹49.57 crores. However, when compared year-over-year (YoY) to the third quarter of the fiscal year 2025 (Q3FY25), there was a significant decline of 34.0%, as the total income stood at ₹88.85 crores in Q3FY25. This fluctuation highlights the variability in revenue generation over the periods in question.
Profitability
The profitability metrics for Mangalam Drugs and Organics Ltd during Q3FY26 show a challenging financial period. The company reported a loss before tax of ₹9.84 crores, which, although an improvement of 21.1% compared to the loss of ₹12.47 crores in Q2FY26, marks a substantial decline from a profit of ₹1.37 crores in Q3FY25. The profit after tax was also negative at ₹9.84 crores, with a 33.9% increase in the loss from the previous quarter's ₹7.35 crores. Year-over-year, this reflects a drastic decline from a profit of ₹1.29 crores in Q3FY25, marking a YoY change of -862.8%. The earnings per share followed a similar trend, deteriorating from ₹0.81 in Q3FY25 to -₹6.21 in Q3FY26.
Operating Metrics
The total expenses for Q3FY26 were ₹68.43 crores, which is a 20.0% increase from the ₹57.01 crores reported in Q2FY26. Compared to Q3FY25, total expenses decreased by 21.8% from ₹87.48 crores. Taxation for Q3FY26 was reported at ₹0.00 crores, indicating no tax liability for the quarter, a notable change from the tax credit of ₹5.12 crores in Q2FY26 and a tax expense of ₹0.08 crores in Q3FY25. These metrics highlight the cost structure dynamics and the impact on overall financial performance for the period under review.